Evotec AG has achieved the second milestone in its four-year Alzheimer’s drug discovery collaboration with Takeda Pharmaceutical Co. Ltd., triggering a milestone payment of more than $1.3 million. Evotec granted Takeda exclusive rights to a novel target in Alzheimer’s disease. Evotec is now eligible for future milestone payments on the successful development of compounds acting on the selected target. Also, Evotec is entitled to further milestone payments should Takeda select additio...